Preoperative Radiotherapy and Local Excision in Rectal Cancer
Launched by POLISH COLORECTAL CANCER STUDY GROUP · Aug 19, 2008
Trial Information
Current as of April 30, 2025
Unknown status
Keywords
ClinConnect Summary
Local excision must involve all tissue invaded on pretreatment examination. For this reason, 4-5 tatoos of mucosa at the tumour border should be performed before the onset of treatment. Next, the long-course radiochemotherapy or short-course radiotherapy is randomly allocated. After 6 weeks interval, the full thickness local excision should be carried out with 1 cm margin. Patients with good pathological response (complete response or downstaging to ypT1 disease)are followed up. Conversion to open surgery is offered to patients with poor pathological response (ypT2-3 or positive margin). Cl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Biopsy proven good or moderately differentiated adenocarcinoma of rectum
- • Extraperitoneal tumour (\< 3-4 cm; unfavourable cT1 or cT2-3; N0)
- • No evidence of distant metastases on chest X-ray and abdominal CT or sonography
- • Signed by patient written informed consent
- Exclusion Criteria:
- • Poorly differentiated pathology (G3)
- • Patients unfit for chemotherapy
- • No agreement for randomisation
About Polish Colorectal Cancer Study Group
The Polish Colorectal Cancer Study Group is a leading research consortium dedicated to advancing the understanding and treatment of colorectal cancer through innovative clinical trials. Comprising prominent oncologists, researchers, and healthcare professionals across Poland, the group focuses on multidisciplinary approaches to enhance patient outcomes and improve therapeutic strategies. By fostering collaboration among institutions and leveraging cutting-edge methodologies, the Polish Colorectal Cancer Study Group aims to contribute significantly to the global body of knowledge in colorectal cancer, ultimately striving to translate research findings into effective clinical practices for better patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Patients applied
Trial Officials
Krzysztof Bujko, Prof.
Principal Investigator
Roentgena 5, 02-781 Warsaw, Poland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials